Status:
COMPLETED
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
Lead Sponsor:
Armando Santoro, MD
Conditions:
NON-SMALL-CELL LUNG CANCER
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGF...
Detailed Description
DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.
Eligibility Criteria
Inclusion
- Availability of tumor tissue or blood samples.
- Diagnosis of NSCLC
- At least one treatment with EGFR-TKIs inhibitors
Exclusion
- Other than NSCLC primary diagnosis
- No treatment with EGFR-TKIs inhibitors
- No archival tissue available
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00831454
Start Date
September 1 2008
End Date
December 1 2011
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinco Humanitas
Rozzano, Mialno, Italy, 20089